Toripalimab was Coherus Oncology’s largest product and service line in fiscal 2025, bringing in $40.84M of $42.17M (97%).
| Product and Service | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Net Product Revenue | — | — | — | — | ||||
| Sales Of Udenyca | — | — | — | — | ||||
| Udenyca | $203.81M | $127.06M | — | — | ||||
| Cimerli | $6.95M | $125.39M | — | — | ||||
| Toripalimab | — | — | $19.13M | $40.84M | ||||
| Toripalimab (Loqtorzi) | — | $554.00K | — | — | ||||
| Yusimry | — | $3.57M | — | — | ||||
| Other Revenue | $282.00K | $664.00K | $7.26M | $1.34M | ||||
| Other | — | — | — | — | ||||
| Collaboration & License Revenue | — | — | — | — | ||||
| Total | $211.04M | $257.24M | $26.39M | $42.17M |
Coherus Oncology brought in $42.17M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 59.8% from $26.39M in fiscal 2024. Toripalimab was the largest at $40.84M (96.8%), ahead of Other Revenue at $1.34M (3.2%).
Compared with fiscal 2024, Toripalimab grew 113.5% to $40.84M, while Other Revenue fell 81.6% to $1.34M.
Coherus Oncology began breaking out Toripalimab in fiscal 2024, when it brought in $19.13M. Coherus Oncology stopped reporting Udenyca ($127.06M in fiscal 2023), Cimerli ($125.39M in fiscal 2023), Yusimry ($3.57M in fiscal 2023) and one other as separate lines.
Rest Of World was Coherus Oncology’s largest region in fiscal 2017, bringing in $1.56M of $3.11M (50%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|
| United States | $28.48M | $27.80M | $188.29M | — | ||
| Rest Of World | $2.63M | $2.24M | $1.81M | $1.56M | ||
| Rest Of The World | — | — | — | $1.56M | ||
| Total | $31.11M | $30.04M | $190.11M | $3.11M |
Coherus Oncology brought in $3.11M from its two regions in fiscal 2017, the year ended December 31, 2017. Coherus Oncology regrouped these regions after fiscal 2016, so the total does not compare directly with that year's $190.11M. Rest Of World was the largest at $1.56M (50.0%), ahead of Rest Of The World at $1.56M (50.0%).
Coherus Oncology began breaking out Rest Of The World in fiscal 2017, when it brought in $1.56M. Coherus Oncology stopped reporting United States as a separate region after fiscal 2016, when it brought in $188.29M.
Coherus Oncology (CHRS) reports its revenue by product and service and by geography. In fiscal 2025, Toripalimab was its largest product and service line, bringing in $40.84M (96.8% of the total), followed by Other Revenue at $1.34M (3.2%).
Toripalimab was Coherus Oncology's largest product and service line in fiscal 2025, bringing in $40.84M, or 96.8% of the $42.17M total across its two product and service lines.
Rest Of World was Coherus Oncology's largest region in fiscal 2017, bringing in $1.56M, or 50.0% of the $3.11M total across its two regions.
Toripalimab grew faster than Other Revenue in fiscal 2025, up 113.5% from $19.13M to $40.84M. Other Revenue fell 81.6% to $1.34M.
Every figure comes from Coherus Oncology's annual financial filings, as reported. Each line keeps the name Coherus Oncology gives it, and years follow its fiscal calendar.
Coherus Oncology's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.